Skip to main content
Institutional profile

Dynavax

Dynavax documents scientific employment alongside tuition reimbursement, confidential employee assistance and wellness support. These provide practical resources around a professional career, without being presented as proof that every scientist receives the same training or working arrangement.

  • Employer

Overview

Dynavax documents scientific employment alongside tuition reimbursement, confidential employee assistance and wellness support. These provide practical resources around a professional career, without being presented as proof that every scientist receives the same training or working arrangement. Current ownership is explicit: Sanofi completed its acquisition in February 2026, with Dynavax continuing as a subsidiary.

The employee record also documents a staff retreat and community activity. Its provider profile was updated in May 2025, before the acquisition, so those findings are not described as a new post-integration survey. The benefits and careers material supply corroborating provision, while the assessment does not assume that all historical employee experiences transfer unchanged through an ownership transition.

Published profile: Top 30 Employers for Research & Innovation Careers 2027 — Dynavax.

At a glance

Assessed U.S. headquarters / baseEmeryville, CA, US
Reported business origins1996
Ownership updateSanofi completed its acquisition on 10 February 2026; Dynavax became an indirect wholly owned subsidiary and its shares ceased Nasdaq trading.

Principal activities and assessed operations

The category profiles below describe the named businesses, products, programmes or employee groups assessed in the linked rankings. Their scope follows each source.

Top 30 Employers for Research & Innovation Careers 2027 — Dynavax

Dynavax documents scientific employment alongside tuition reimbursement, confidential employee assistance and wellness support. These provide practical resources around a professional career, without being presented as proof that every scientist receives the same training or working arrangement. Current ownership is explicit: Sanofi completed its acquisition in February 2026, with Dynavax continuing as a subsidiary.

The employee record also documents a staff retreat and community activity. Its provider profile was updated in May 2025, before the acquisition, so those findings are not described as a new post-integration survey. The benefits and careers material supply corroborating provision, while the assessment does not assume that all historical employee experiences transfer unchanged through an ownership transition.

  • Employing entity / assessed group: Dynavax (assessed U.S. employing group)
  • Assessed workforce: US employees in documented scientific/research-development work and professional support; role and programme eligibility applies.
  • Assessed U.S. headquarters / base: Emeryville, CA, US
  • Reported business origins: 1996

Top 30 Pharmaceutical & Biotechnology Employers 2027 — Dynavax

Dynavax’s published benefits identify tuition reimbursement, confidential employee assistance and the Wellable wellness program. Its provider profile documents a staff retreat and community involvement. Sanofi completed its acquisition in February 2026, with Dynavax continuing as a subsidiary; the entry therefore identifies the current ownership rather than presenting it as an independent public company.

Great Place To Work’s U.S. profile, updated May 2025, reports 90% overall workplace endorsement. A published employee item records 96% agreement: “I am able to take time off from work when I think it's necessary.”

  • Assessed workforce: U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded. Legacy Dynavax survey predates February 2026 Sanofi acquisition; no Sanofi-wide or post-integration inference.

Activities covered by the rankings

Rankings and recognition — 2027

Recorded appearances in The Economy Rankings. Each entry concerns the assessed business, product, institution or workforce scope in the linked edition.

RankingEdition / classificationAssessed scope
Employers for Research & Innovation Careers2027 · Tier IIIUS employees in documented scientific/research-development work and professional support; role and programme eligibility applies.
Pharmaceutical & Biotechnology Employers2027 · Tier IIIU.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded. Legacy Dynavax survey predates February 2026 Sanofi acquisition; no Sanofi-wide or post-integration inference.

Explore The Economy

The following articles provide wider sector context. They are not necessarily coverage of this specific entity or an endorsement by it.

Documented company information

February 2026 closing filing identifies principal executive offices at 2100 Powell Street, Suite 720, Emeryville, California. Source.

Sanofi completed acquisition February 10, 2026; Dynavax survived as an indirect wholly owned subsidiary and Nasdaq share trading ceased. Source.

Further reference

Corrections and Updates

Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.

Profile type: Company

Reviewed: 25 October 2026

The Economy Wiki

Initial reference profile based on the linked ranking editions. Additional documented company or institutional information can be incorporated in subsequent updates.